Asia

START expands with phase I center in Shanghai

Thursday, September 22, 2011 10:45 AM

South Texas Accelerated Research Therapeutics (START), a US-based group that claims to run the world’s largest co-ordinated network of phase I clinical trials in oncology, has opened a phase I research facility in China at Fudan University Shanghai Cancer Centre, the city’s largest cancer hospital, according to PharmaTimes.

More... »

OpenClinica, Athena partner to provide clinical trial support in China

Thursday, August 25, 2011 01:25 PM

OpenClinica has entered into a strategic alliance with Athena Healthcare Consultancy to bring the OpenClinica clinical trials software to the Chinese market. Headquartered in Shanghai, Athena will be the exclusive distributor of the OpenClinica enterprise edition and provide localized support and services for contract research organizations, pharmaceutical companies, and scientific institutes operating in China, according to Digital Journal.

More... »

StudyManager Evolve continues to expand in Chinese market

Friday, August 19, 2011 10:20 AM

StudyManager, a leading provider of integrated clinical trial management software (CTMS) and electronic data capture (EDC) solutions, has reported that GCP ClinPlus, a clinical research organization (CRO) in China, and Chongqing Jiachen Biotechnology have deployed StudyManager’s Evolve software to manage their latest clinical studies.

More... »

Report: clinical teams outsourcing in Asia now focusing on smaller markets

Thursday, July 21, 2011 12:44 PM

A new report says clinical development teams looking for outsourcing opportunities in Asia are turning their attention to smaller emerging markets rather than automatically plumping for established territories such as India and China, according to Pharma-Times.

More... »

China to spend billions on biotech development

Tuesday, July 5, 2011 12:27 PM

China will spend $308.5 billion on science and technology, making biotechnology a major priority in the next five years, said Chinese State Councilor Liu Yandong, according to China Daily. 

More... »

Singapore R&D consortium aims to tap into outsourcing trend

Tuesday, June 28, 2011 02:32 PM

Government agency International Enterprise (IE) Singapore has launched a biomedical R&D consortium involving seven companies based in the island state, with the aim of tapping into the trend for outsourcing of R&D across Asia, according to PharmaTimes.

More... »

Indian regulators suspend operations at CRO Axis Clinicals

Tuesday, June 28, 2011 02:30 PM

India’s Drug Controller General (DGCI) has suspended operations at Hyderabad, India-based CRO Axis Clinicals and is vetting all bioavailability and bioequivalence study centers in Andhra Pradesh state after investigations revealed irregularities in a trial conducted by Axis, reported PharmaTimes.

More... »

Shanghai Pharma's IPO to top $2.1 billion

Friday, May 13, 2011 11:44 AM

Shanghai Pharmaceuticals has priced its proposed initial public offering in Hong Kong, which will top $2.13 billion, according to Pharma Times.

More... »

Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

More... »

SciClone acquires NovaMed Pharmaceuticals

Tuesday, April 19, 2011 12:20 PM

California-based SciClone Pharmaceuticals has acquired NovaMed Pharmaceuticals, a China-based specialty pharmaceutical company, according to Fierce Biotech. The acquisition brings more sales and marketing as well as regulatory and business capabilities.  The pharmaceutical assets in the regulatory approval stage add to SciClone’s growing and profitable China-focused specialty pharmaceutical business.

More... »